Trial Profile
Efficacy and Safety of Deferiprone in Treatment-Nave and Non-Treatment-Nave Patients with Parkinsons Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms EMBARK
- Sponsors ApoPharma
- 07 Jan 2020 Status changed from active, no longer recruiting to completed.
- 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2017 New trial record